ROC Inc is raising awareness for rare ovarian cancer by hosting discussions with leading experts in research and treatment.
Enter your name and email to register to view the recording. If you previously attended or registered for the webinar, you can use the link in your confirmation or recording published email.
Granulosa Cell Tumour GCT, a rare ovarian cancer Q&A on Treatment, Challenges and Research
Tasha Armour founder and CEO of Rare Ovarian Cancer Incorporated – ROC Inc. talks to three leading international experts on Granulosa Cell Tumours GCT.
Dr Simon Chu research head of Hormone Cancer Therapeutic Laboratory at the Hudson Institute of Medical Research.
Professor Peter Fuller AM is physician-scientist who leads the Centre for Endocrinology and Metabolism at the Hudson Institute of Medical Research. Head of Endocrinology Unit, Monash Health
Professor Tom Jobling OAM, Director of Gynaecology Oncology at Monash Health
Granulosa Cell Tumour GCT has two subtypes adult aGCT and juvenile jGCT this is an opportunity to hear about what the latest developments for both of these subtypes and what is the future direction is for research and treatment for all GCT.